Treatment of Hypertension With Adalat® in Combination With Other Drugs
- Registration Number
- NCT01118286
- Lead Sponsor
- Bayer
- Brief Summary
To investigate the therapeutic effectiveness of long acting nifedipine containing combination therapy in the treatment of hypertensive patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 4497
Inclusion Criteria
- Previously untreated hypertensive patients starting with combination therapy containing nifedipine or
- Insufficiently controlled hypertensive pts. receiving nifedipine as an add-on to existing non-CCB (calcium-channel-blocker) containing antihypertensive therapy
Read More
Exclusion Criteria
- None. Exclusion criteria are defined by contraindications and precautions as stated in the local product information.
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Group 1 Nifedipine (Adalat, BAYA1040) -
- Primary Outcome Measures
Name Time Method Evaluation of treatment success (lowering of blood pressure in mmHg) in adult hypertensive patients After three months
- Secondary Outcome Measures
Name Time Method